Menu Search
Equities

Abbott Laboratories

ABL:STU

Abbott Laboratories

Actions
  • Price (EUR)95.54
  • Today's Change-0.28 / -0.29%
  • Shares traded0.00
  • 1 Year change-12.78%
  • Beta--
Data delayed at least 15 minutes, as of May 29 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.

  • Revenue in USD (TTM)41.51bn
  • Net income in USD5.80bn
  • Incorporated1900
  • Employees115.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttps://www.abbott.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ABT:NYQ since
announced		Transaction
value
Cardiovascular Systems IncDeal completed08 Feb 202308 Feb 2023Deal completed-9.14%840.49m
Data delayed at least 15 minutes, as of May 30 2023 20:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.